Recursion

Bottom line

Recursion is not a point-of-care clinical tool, and clinicians cannot purchase it for their practice. It is a drug discovery platform operated by Recursion Pharmaceuticals, a publicly traded biotech company that uses phenomics and machine learning to accelerate early-stage pharmaceutical research. Following its 2024 merger with Exscientia, the combined entity offers pharma companies access to one of the largest proprietary biological and chemical datasets in the industry, paired with computational models designed to predict drug candidates with higher success rates than traditional high-throughput screening.

This is an enterprise partnership model with no public pricing. Access requires negotiating a multi-year R&D collaboration, typically at the scale of tens of millions of dollars. The platform does not integrate with EHRs, does not require HIPAA compliance in the clinical sense, and is not deployed in hospitals. Its output is drug candidates that may reach clinical trials in 3 to 5 years and FDA approval in 8 to 12 years, assuming success.

If you are a CMIO, hospital IT leader, or practicing clinician evaluating AI tools for your workflow, Recursion is the wrong category. If you are a pharma R&D executive or academic translational research leader exploring AI-driven discovery partnerships, Recursion belongs on your shortlist alongside BenevolentAI, Insitro, and Insilico Medicine. The evidence base for clinical utility is indirect and long-term: better drug candidates may eventually improve patient outcomes, but that chain of causation is measured in decades, not deployment cycles.

Why we picked it

Recursion was not selected as a silo pick for clinical practice tools because it does not fit that category. It appears in this review as a representative of the AI-driven drug discovery vertical, where it ranks among the top five platforms globally by dataset scale, partnership volume, and public market capitalization. The 2024 merger with Exscientia combined two complementary approaches: Recursion's phenomics-first screening (imaging-based cellular response profiling at scale) and Exscientia's generative chemistry models (structure-based molecular design). The resulting platform offers pharma partners dual modalities under one contract.

The company has disclosed partnerships with Roche, Bayer, and Takeda, among others, and maintains a proprietary pipeline of wholly owned programs in oncology, rare diseases, and infectious diseases. Its public disclosures indicate over 20 programs in preclinical or clinical stages, a scale that reflects both the platform's productivity and the inherent attrition rate of drug development.

From a research institution or pharma perspective, Recursion represents a vertically integrated stack: wet lab automation, high-content imaging, proprietary compound libraries, and ML infrastructure under one roof. This reduces coordination overhead compared to stitching together multiple vendors. For clinicians or health systems, however, the relevance is speculative: the platform's success is measured in IND filings and Phase 1 starts, not in workflow acceleration or diagnostic accuracy.

If this were framed as a drug discovery platform review for pharma R&D audiences, Recursion would score highly for data scale and integration depth. Framed as a clinical tool review, it scores zero for applicability.

What it does well

Recursion has built one of the largest proprietary biological image datasets in the pharmaceutical industry, with over 50 petabytes of high-content microscopy images capturing cellular responses to chemical and genetic perturbations. This phenomics approach allows the platform to identify drug candidates by observing how cells change morphology, protein localization, and signaling activity in response to compounds, rather than relying solely on target-based screening. The breadth of this dataset enables transfer learning across disease areas: a model trained on oncology phenotypes can inform rare disease hypotheses, reducing the cost of exploratory programs.

The Exscientia merger brought generative chemistry capabilities that complement Recursion's screening strengths. Exscientia's models are trained on protein-ligand binding data and can propose novel molecular structures optimized for potency, selectivity, and ADMET properties. The integrated workflow allows Recursion to screen broadly for phenotypic hits, then iteratively refine those hits using generative design, creating a closed-loop discovery cycle. This integration is still maturing, but early disclosures suggest the combined platform has shortened hit-to-lead timelines by 30 to 40 percent in select programs.

The company operates its own wet lab automation infrastructure, including custom-built imaging systems and robotic liquid handlers, which gives it control over data quality and throughput. This vertical integration reduces reliance on contract research organizations for early-stage work and allows rapid iteration when ML models flag unexpected biology. Pharma partners value this because it compresses the cycle time between computational prediction and experimental validation.

Recursion has also demonstrated an ability to publish its methods in peer-reviewed journals and open-source portions of its tooling, which builds credibility in the academic and pharma research communities. The company's collaboration with NVIDIA on GPU-accelerated model training has positioned it as a reference implementation for large-scale biological ML, attracting talent and partnership interest.

Where it falls short

The most significant limitation for any audience considering Recursion is the opacity of its partnership terms and the absence of public clinical validation. No Recursion-discovered drug has yet received FDA approval. The company's pipeline includes multiple Phase 1 and Phase 2 trials, but the modal outcome in drug development is failure: industry-wide, fewer than 10 percent of candidates that enter Phase 1 reach approval. Recursion's platform may improve those odds, but the evidence for that claim remains proprietary and anecdotal.

Pricing is entirely undisclosed. Partnership announcements with Roche and Bayer mention upfront payments in the range of $50 million to $150 million, plus milestone payments and royalties, but the cost structure for smaller biotech or academic partnerships is unknown. This makes it impossible for a research institution to budget for access without engaging in lengthy negotiations. The lack of transparent tier pricing, unlike SaaS clinical tools, limits accessibility to well-funded organizations.

For clinical audiences, the platform has no direct applicability. It does not assist with diagnosis, treatment selection, documentation, or care coordination. It does not integrate with EHRs, does not handle patient data in HIPAA-regulated contexts, and does not accelerate clinician workflows. A hospitalist, radiologist, or primary care physician gains nothing from Recursion's existence unless and until a Recursion-discovered drug reaches their formulary, a timeline measured in years to decades.

The merger with Exscientia introduced integration risk. Combining two platforms with different data models, training pipelines, and partnership obligations is complex, and the merged entity has not yet published detailed case studies showing superior outcomes compared to pre-merger performance. Early partnership renewals and new deals suggest the integration is proceeding, but independent validation is absent.

Deployment realities

Deployment is the wrong framing for Recursion. It is not software installed in a hospital or clinic. Access is granted through R&D partnership agreements, typically structured as multi-year collaborations with defined therapeutic areas, milestone-based payments, and IP-sharing terms. A pharma partner does not deploy Recursion; it contracts for discovery services and computational support, with Recursion scientists embedded in joint steering committees.

For academic research institutions, engagement might take the form of sponsored research agreements or data-sharing partnerships. These require institutional review board approval if human-derived samples are involved, compliance with export control regulations if the institution has international collaborators, and alignment on publication rights. The overhead is substantial and typically requires dedicated technology transfer and legal support.

There is no training burden for end-user clinicians because clinicians are not end users. Pharma R&D scientists and computational biologists are the users, and they require familiarity with high-content imaging, cheminformatics, and ML model interpretation. Recursion provides onboarding and support as part of partnership agreements, but this is scientist-to-scientist technical transfer, not clinical workflow training.

Pricing realities

Recursion does not publish pricing tiers. The company describes its model as enterprise partnerships, which in disclosed deals have involved upfront payments of $50 million to $150 million, milestone payments tied to clinical progress that can exceed $1 billion over the life of a successful program, and single-digit royalties on net sales if a drug reaches market. These figures are public only when disclosed in SEC filings or partnership press releases, and they vary widely based on the scope of the collaboration, the number of therapeutic areas, and the exclusivity terms.

There is no per-seat, per-API-call, or subscription pricing. A hospital cannot purchase Recursion access for $10,000 per month. A solo practitioner cannot access it at all. The minimum viable engagement is likely in the low millions of dollars annually, which restricts access to large pharma, well-funded biotech, and top-tier academic medical centers with substantial industry partnerships.

Hidden costs include the need for internal computational biology and cheminformatics teams to interpret Recursion's outputs, the cost of follow-on wet lab validation (even with Recursion's automation, partners often run independent confirmation studies), and the opportunity cost of committing to a multi-year exclusive partnership in a given therapeutic area, which may preclude working with competing platforms like Insitro or BenevolentAI during the contract term.

Compliance + integration depth

Recursion operates under Good Laboratory Practice and Good Manufacturing Practice standards where applicable to its internal drug development programs, but it is not a covered entity under HIPAA. The platform does not handle protected health information in the clinical sense. If a partnership involves human-derived biospecimens or genomic data, those are governed by informed consent protocols, institutional review board oversight, and data use agreements, not by HIPAA business associate agreements.

There is no EHR integration because there is no clinical workflow integration. Recursion does not write to Epic, Cerner, or any other EHR. It does not pull patient data from hospital systems. The platform's data inputs are experimentally generated: cell lines, primary cells, organoids, and compound libraries, all produced in controlled laboratory settings. Clinical data may inform target selection at the partnership strategy level (e.g., analyzing genomic databases to prioritize oncology targets), but that is upstream research, not real-time clinical decision support.

The company's SOC 2 Type II certification and ISO 27001 compliance, if publicly disclosed, would be relevant for pharma partners concerned about IP protection and data security, but these certifications do not address clinical safety or regulatory categories like FDA 510(k) or CE marking for medical devices. Recursion's platform is a research tool, not a diagnostic or therapeutic device subject to FDA premarket approval.

Vendor stability + roadmap

Recursion Pharmaceuticals is publicly traded on NASDAQ under the ticker RXRX, which provides transparency into its financial position. As of its most recent quarterly filing, the company reported over $300 million in cash and equivalents, sufficient to fund operations into 2027 at current burn rates. The 2024 merger with Exscientia was structured as an all-stock transaction, with Recursion as the surviving entity. The combined company employs over 500 people across sites in Salt Lake City, Oxford, and other locations.

The merger has created integration risk, but early signals suggest the partnership pipeline remains active. Roche extended its collaboration in 2025, and new partnerships with undisclosed biotech firms have been announced. The leadership team includes co-founder and CEO Chris Gibson, a computational biologist with a track record of academic publications and prior pharma collaborations, which lends credibility to the scientific strategy.

The roadmap, based on public disclosures and investor presentations, emphasizes expanding the phenomics dataset to include more disease-relevant cell types (e.g., patient-derived organoids, iPSC-derived neurons), integrating multiomics data (transcriptomics, proteomics), and scaling generative chemistry models to design entire compound libraries rather than iterative optimization. The company has also signaled interest in applying its platform to biologics discovery (antibodies, gene therapies), though this remains early-stage.

How it compares

Recursion competes with BenevolentAI, Insitro, Insilico Medicine, Atomwise, and Schrödinger in the AI-driven drug discovery space. BenevolentAI emphasizes knowledge graph-based target identification, integrating biomedical literature and clinical trial data to prioritize hypotheses. Insitro focuses on induced pluripotent stem cell models and machine learning on cellular assays, similar to Recursion's phenomics approach but with a tighter focus on specific disease areas. Insilico Medicine has publicly disclosed FDA clinical trial starts for generative chemistry-designed candidates, giving it a lead in demonstrating real-world clinical translation.

Atomwise specializes in structure-based virtual screening at massive scale, using convolutional neural networks to predict protein-ligand binding. It has a broader partnership footprint than Recursion, with over 750 disclosed collaborations, but those partnerships are typically narrower in scope (target-specific screening campaigns rather than multi-year platform access). Schrödinger offers a hybrid model: commercial software licenses for computational chemistry tools plus fee-for-service discovery collaborations, which makes it accessible to smaller biotech that cannot afford Recursion's partnership minimums.

Recursion's differentiation lies in its vertical integration: owning the wet lab, the imaging infrastructure, the compound libraries, and the ML stack under one roof. This reduces handoff friction but increases capital requirements and operational complexity. BenevolentAI and Insitro operate similarly integrated models, while Atomwise and Schrödinger are more modular. For a pharma partner, Recursion is the right choice when the goal is broad phenotypic exploration across multiple targets in a therapeutic area. Insilico or Atomwise may be preferable for hit identification on a single well-characterized target.

None of these platforms have yet delivered an FDA-approved drug from AI-first discovery, so head-to-head efficacy comparisons are speculative. Partnerships disclosed, pipeline depth, and public market valuations serve as rough proxies, where Recursion ranks in the top three by market cap and partnership count.

What clinicians say

Clinician commentary on Recursion is sparse and indirect. The platform has been mentioned nine times in discussions on Reddit forums frequented by physicians, residents, and researchers, but these mentions are overwhelmingly speculative or science-focused rather than experiential. Clinicians do not use Recursion in practice, so there are no workflow reviews, training burden complaints, or EHR integration frustrations to surface.

Where Recursion appears in clinician discussions, it is typically in the context of broader AI-in-medicine debates: skepticism about vendor hype, cautious optimism about drug discovery acceleration, and frustration with the slow pace of translating computational biology breakthroughs into formulary additions. One representative sentiment from a hospitalist on r/medicine noted that AI drug discovery platforms are interesting in principle but irrelevant to day-to-day practice unless they produce drugs that materially outperform existing therapies, a bar that no Recursion candidate has yet cleared.

The absence of user-generated reviews is not a flaw of the platform; it reflects the category mismatch. Recursion's real users are pharma R&D teams and computational biologists, who do not typically post detailed reviews on public forums due to confidentiality obligations in partnership agreements.

What the literature says

PubMed coverage of Recursion as a drug discovery platform is limited. Of the five citations provided, only one directly addresses AI-driven drug discovery platforms: a 2026 review in Pharmacological Reviews titled "Leading artificial intelligence-driven drug discovery platforms: 2025 landscape and global outlook." That review compares five platforms, including Recursion, and notes that phenomics-based approaches have generated diverse pipelines but have yet to produce clinical proof-of-concept data distinguishing them from traditional discovery methods in terms of Phase 2 or Phase 3 success rates.

The other four citations are unrelated: studies on psychotherapeutic recursion theory, mass spectrometry methods for herbal compounds, cognitive science experiments on visual recursion, and medical image segmentation algorithms. None of these discuss Recursion Pharmaceuticals or its platform. The scarcity of peer-reviewed literature evaluating Recursion's clinical impact is expected given that the platform's outputs are drug candidates still in early-stage trials. Independent academic validation of the platform's predictive accuracy, throughput advantages, or clinical translatability has not yet been published in high-impact journals.

The evidence gap is significant. For a clinical tool like an AI-based diagnostic or a clinical decision support system, the absence of peer-reviewed validation studies would be disqualifying. For a drug discovery platform, the relevant evidence will emerge only after candidates reach late-stage trials and comparative effectiveness can be assessed. Until then, adoption decisions rest on partnership due diligence, preclinical data shared under confidentiality, and the reputational track record of the leadership team.

Who it's for

Recursion is for pharmaceutical companies with R&D budgets in the hundreds of millions of dollars, biotech firms seeking to build pipelines in therapeutic areas where Recursion has demonstrated traction (oncology, rare diseases, infectious diseases), and academic medical centers with translational research institutes capable of negotiating industry partnerships and managing complex IP agreements. It is a fit for organizations that can absorb the financial risk of multi-million-dollar upfront commitments, the operational complexity of integrating external computational models into internal discovery workflows, and the long timelines inherent to drug development.

It is not for solo practitioners, small group practices, community hospitals, or health system IT departments. It is not for CMIOs evaluating clinical decision support tools, radiology AI, or ambient documentation systems. It is not for residents seeking workflow automation or hospitalists looking to reduce administrative burden. The value proposition is entirely upstream of clinical care: better drug candidates may eventually improve patient outcomes, but that benefit is indirect, delayed, and contingent on FDA approval and formulary adoption.

Academic research institutions considering Recursion should have in-house expertise in computational biology, access to disease-relevant biospecimens, and existing pharma partnerships that can co-fund the collaboration. Institutions without those assets are unlikely to meet the partnership threshold. For pharma R&D executives, Recursion belongs on the evaluation shortlist if the strategic priority is phenomics-driven exploration or if the Exscientia generative chemistry integration aligns with internal capabilities gaps.

The verdict

Recursion is a well-capitalized, scientifically credible drug discovery platform with a differentiated dataset and a post-merger integration that expands its technical scope. For the audience this review is written for, practicing physicians, residents, healthcare administrators, CMIOs, and IT leaders evaluating clinical AI tools, Recursion is categorically irrelevant. It is not deployed in hospitals, does not integrate with EHRs, does not assist with clinical workflows, and cannot be purchased at any price point accessible to individual practitioners or health systems.

For pharmaceutical R&D leaders and academic translational research institutes, Recursion is a credible option in a competitive field. The platform's phenomics-first approach, vertical integration, and Exscientia merger position it among the top five AI-driven discovery platforms globally. The absence of FDA-approved drugs from the platform, the opacity of pricing, and the lack of independent peer-reviewed validation of clinical translation success rates are significant limitations. Partnership decisions should be informed by detailed technical due diligence, access to proprietary preclinical data, and alignment on therapeutic area strategy.

If you are a CMIO or hospital IT leader, skip this review and focus on tools that address clinical workflows directly. If you are a pharma R&D executive, request detailed case studies, pipeline data, and partnership terms before committing. The evidence base for Recursion's superiority over traditional discovery methods or competing AI platforms remains preliminary, and adoption should be approached as a calculated R&D investment, not a proven clinical intervention.